Initial Statement of Beneficial Ownership (3)
07 Gennaio 2021 - 10:56PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Li Dean Y |
2. Date of Event Requiring Statement (MM/DD/YYYY)
1/1/2021
|
3. Issuer Name and Ticker or Trading Symbol
Merck & Co., Inc. [MRK]
|
|
(Last)
(First)
(Middle)
MERCK & CO., INC., 2000 GALLOPING HILL ROAD |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
Executive VP & President, MRL / |
|
(Street)
KENILWORTH, NJ 07033
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4) | 2. Amount of Securities Beneficially Owned
(Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) | 4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Common Stock | 7170.093 (1) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4) | 2. Date Exercisable and Expiration Date
(MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) | 6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Restricted Stock Unit | 5/4/2019 (2) | 5/4/2021 | Common Stock | 694 | (3) | D | |
| Restricted Stock Unit | 5/3/2020 (4) | 5/3/2022 | Common Stock | 1500 | (3) | D | |
| Restricted Stock Unit | 5/1/2021 (5) | 5/1/2023 | Common Stock | 3090 | (3) | D | |
| Stock Option (Right to Buy) | 5/5/2018 (6) | 5/4/2027 | Common Stock | 14265 | $63.97 | D | |
| Stock Option (Right to Buy) | 5/4/2019 (7) | 5/3/2028 | Common Stock | 14638 | $57.75 | D | |
| Stock Option (Right to Buy) | 5/3/2020 (8) | 5/2/2029 | Common Stock | 16936 | $80.00 | D | |
| Stock Option (Right to Buy) | 5/1/2021 (9) | 4/30/2030 | Common Stock | 24165 | $77.67 | D | |
| Explanation of Responses: |
| (1) | Holdings include shares acquired in dividend reinvestment transactions. |
| (2) | These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. |
| (3) | Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. |
| (4) | These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022. |
| (5) | These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. |
| (6) | The option became exercisable in equal installments on 5/5/2018, 5/5/2019 and 5/5/2020. |
| (7) | The option vests and becomes exercisable in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. |
| (8) | The option vests and becomes exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022. |
| (9) | The option vests and becomes exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. |
Remarks:
See Exhibit 24 - Power of Attorney |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Li Dean Y
MERCK & CO., INC.
2000 GALLOPING HILL ROAD
KENILWORTH, NJ 07033 |
|
| Executive VP & President, MRL |
|
Signatures
|
| /s/ Kelly Grez as Attorney-in-Fact for Dean Y. Li | | 1/7/2021 |
| **Signature of Reporting Person | Date |
Grafico Azioni Merck (NYSE:MRK)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Merck (NYSE:MRK)
Storico
Da Apr 2023 a Apr 2024
